BEDMINSTER, N.J., June 22, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc.(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced that it received a Notice of Issuance from the U.S. Patent and Trademark Office (“USPTO”) for U.S. Patent Application Serial No. 14/609,235 entitled, “Cochleates Made with Soy Phosphatidylserine.” The patent has been issued as U.S. Patent No. 9,370,572 and provides intellectual property protection through 2033.
The issued patent claims cover proprietary methods related to the composition, methods, formulation and use of Matinas BioPharma’s lipid-crystal nano-particle cochleate formulation technology. The patent also includes pharmaceutical treatment of use claims for the Company’s orally-administered lead anti-infective product candidates, MAT2203 (encochleated amphotericin B, a broad spectrum fungicidal medication) and MAT2501 (encochleated amikacin, a broad spectrum aminoglycoside antibiotic agent).
MAT2203 is an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). Little to no clinical resistance has been reported to date with amphotericin B as compared to the rapidly emerging drug resistance seen in other antifungal therapies. Currently, IV-only administered amphotericin B is the only broad spectrum fungicidal available but its IV-delivery results in significant treatment-limiting side effects, including nephrotoxicity. The ability to provide amphotericin B via MAT2203’s proprietary and novel oral formulation may offer a new and promising alternative for patients and doctors. In a clinical Phase 1a single-dose, double-blind, dose-escalating, pharmacokinetic study of 48 healthy volunteers, oral MAT2203 demonstrated a positive safety and tolerability profile with no serious adverse events reported, including little or no nephrotoxicity as compared to placebo. Enrollment is currently underway for the Phase 2a NIH/NIAID-funded clinical study with MAT2203 in patients with refractory mucocutaneous candidiasis, with results expected during 2016. MAT2203 is also being explored for treatment of additional anti-fungal indications and may have the potential for Orphan Drug Designation in certain of these indications.